Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2021 SECOND EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 14 JULY 2021(H SHARES)

07/14/2021 | 06:55am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥(集 團)股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTION PROPOSED

AT THE 2021 SECOND EXTRAORDINARY GENERAL MEETING HELD

ON WEDNESDAY, 14 JULY 2021

The board (the "Board") of directors (the "Directors") of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") is pleased to announce the poll results of the 2021 second extraordinary general meeting (the "EGM") held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC on Wednesday, 14 July 2021 at 1:30 p.m..

References are made to the notice of the EGM and the circular of the Company (the "Circular"), both dated 23 June 2021. Unless the context otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, (i) the total number of the issued shares of the Company (the "Shares") was 2,562,898,545 Shares, comprising 2,010,958,045 A Shares and 551,940,500 H Shares; and (ii) holders of 2,562,898,545 Shares (or by authorized proxies) were entitled to attend and vote on the resolution proposed at the EGM. There were no Shares entitling the shareholders of the Company (the "Shareholders") to attend and vote only against the resolution at the EGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting at the EGM.

1

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies

213

Including: Number of A Shareholders

211

Number of H Shareholders

2

Total number of Shares carrying voting rights (shares)

1,187,186,408

Including: Total number of Shares carrying voting rights held by A Shareholders

980,628,478

Total number of Shares carrying voting rights held by H Shareholders

206,557,930

Percentage of the total number of Shares

46.3220%

Including: Number of A Shares as a percentage of the number of Shares

38.2625%

Number of H Shares as a percentage of the number of Shares

8.0595%

The EGM was convened in compliance with the requirements of the Company Law of the People's Republic of China and the articles of association of the Company (the "Articles of Association"), and was chaired by Mr. Wu Yifang, chairman of the Company.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's

PRC legal advisers, Shareholder's representatives and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at EGM.

POLL RESULTS OF THE RESOLUTION PROPOSED AT THE EGM

The resolution at the EGM was voted by poll. The poll results in respect of the resolution proposed at the EGM are as follows:

SPECIAL RESOLUTION

Number of valid votes

For

Against

Abstain

1.

To consider and approve the resolution on the

1,184,434,949

170,507

2,580,952

Report on the Use of Proceeds Previously Raised.

(99.7682%)

(0.0144%)

(0.2174%)

As more than two-thirds of the votes were cast in favour of this resolution, the resolution was

duly passed as a special resolution.

2

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai)* ( 國浩律師 (上海)事務所), the Company's PRC legal advisers, the convening and holding of the EGM are in

compliance with requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

14 July 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non- executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

  • for identification purposes only

3

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 14 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 July 2021 10:54:01 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
09/22SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Raises Nearly $186 Million from Sale of Renmi..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins US FDA Nod to Start Clinical Trial of Ex..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - on completion of the issuance of ..
PU
09/10SHANGHAI FOSUN PHARMACEUTICAL : Proposed adoption of rsu scheme by a subsidiary (h ..
PU
09/02SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
09/01SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Secures Another $100 Million For COVID-19 Vac..
MT
08/25REFILE-Taiwan says BioNTech shots available earlier than expected
RE
08/25REFILE-Taiwan to get BioNTech shots early as China delays approval-source
RE
08/24SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces 2021 Interim Results Innovative Pro..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 37 550 M 5 816 M 5 816 M
Net income 2021 4 674 M 724 M 724 M
Net Debt 2021 17 898 M 2 772 M 2 772 M
P/E ratio 2021 31,0x
Yield 2021 0,89%
Capitalization 115 B 17 827 M 17 852 M
EV / Sales 2021 3,55x
EV / Sales 2022 3,02x
Nbr of Employees 34 375
Free-Float 57,5%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 57,32 CNY
Average target price 68,40 CNY
Spread / Average Target 19,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman